Skip to main content
. 2023 Jan 14;12(2):324. doi: 10.3390/cells12020324

Figure 10.

Figure 10

The therapeutic action of natalizumab and vedolizumab. Integrin antagonists inhibit leukocyte migration into endothelium: (a) leukocyte adhesion cascade, (b) natalizumab binds to both the α4β1 and α4β7 integrins, thus blocking leukocyte adhesion, (c) vedolizumab binds only to the α4β7 integrin, which minimizes potential side effects. Based on ref. [324].